{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:17:00Z","timestamp":1791955020708,"version":"4.3.4"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T00:00:00Z","timestamp":1526428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We retrospectively assessed breakthrough invasive fungal infections (b-IFIs) in 100 consecutive patients with leukemia receiving single-agent isavuconazole; 13 had documented b-IFIs (candidiasis in 6, mucormycosis in 4). All b-IFIs were observed in patients with prolonged neutropenia and active leukemia.<\/jats:p>","DOI":"10.1093\/cid\/ciy406","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T19:14:18Z","timestamp":1525720458000},"page":"1610-1613","source":"Crossref","is-referenced-by-count":54,"title":["Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole"],"prefix":"10.1093","volume":"67","author":[{"given":"Caitlin R","family":"Rausch","sequence":"first","affiliation":[{"name":"Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J","family":"DiPippo","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[{"name":"Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios P","family":"Kontoyiannis","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,16]]},"reference":[{"key":"2024111411404324200_CIT0001","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fmb.15.34","article-title":"Isavuconazole: a new extended spectrum triazole for invasive mold diseases","volume":"10","author":"Ananda-Rajah","year":"2015","journal-title":"Future Microbiol"},{"key":"2024111411404324200_CIT0002","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/423274","article-title":"Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole","volume":"39","author":"Imhof","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024111411404324200_CIT0003","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/cid\/cis773","article-title":"Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry","volume":"55","author":"Pagano","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024111411404324200_CIT0004","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/cid\/cix130","article-title":"Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis","volume":"64","author":"Lamoth","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024111411404324200_CIT0005","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2024111411404324200_CIT0006","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts","author":"Clinical and Laboratory Standards Institute","year":"2012","edition":"4"},{"key":"2024111411404324200_CIT0007","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts","author":"Clinical Laboratory Standards Institute","year":"2012","edition":"4"},{"key":"2024111411404324200_CIT0008","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/cid\/ciy260","article-title":"Breakthrough invasive fungal infections on isavuconazole prophylaxis and treatment: what is happening in the real-world setting","volume":"67","author":"Fung","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024111411404324200_CIT0009","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2024111411404324200_CIT0010","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411404324200_CIT0011","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1093\/jac\/dkv087","article-title":"The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality","volume":"70","author":"Wang","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2024111411404324200_CIT0012","article-title":"Isavuconazole versus caspofungin in the treatment of candidaemia and other invasive Candida infections: the ACTIVE trial","author":"Kullberg","year":"2016","journal-title":"European Congress of Clinical Microbiology and Infectious Diseases, 9\u201312 April 2016"},{"key":"2024111411404324200_CIT0013","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00188-17","article-title":"Real-life assessment of the safety and effectiveness of the new tablet and intravenous formulations of posaconazole in the prophylaxis of invasive fungal infections via analysis of 343 courses","volume":"61","author":"Tverdek","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024111411404324200_CIT0014","article-title":"Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial","author":"Kontoyiannis","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024111411404324200_CIT0015","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/cid\/ciw585","article-title":"Real-life use of isavuconazole in patients intolerant to other azoles","volume":"63","author":"Ordaya","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/67\/10\/1610\/26189615\/ciy406.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/67\/10\/1610\/26189615\/ciy406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:11:58Z","timestamp":1731586318000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/67\/10\/1610\/4996548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,16]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,5,16]]},"published-print":{"date-parts":[[2018,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy406","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11,15]]},"published":{"date-parts":[[2018,5,16]]}}}